Jose Ezekiel Clemente Espina

Jose Ezekiel Clemente Espina

Auto-generated profile, based on publicly available information

Jose Ezekiel Clemente Espina

Department of Neuroscience, University of Wisconsin-Madison School of Medicine and Public Health

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
OHOlivia R. Hoffman
Olivia R. Hoffman
JKJennifer L. Koehler
Jennifer L. Koehler
JEJose Ezekiel Clemente Espina
Jose Ezekiel Clemente Espina
APAnna M. Patterson
Anna M. Patterson
EGEmily S. Gohar
Emily S. Gohar
ARAvtar S. Roopra
Avtar S. Roopra
All current drug treatments for epilepsy, a neurological disorder affecting more than 50 million people, merely treat symptoms, and a third of patients with epilepsy do not respond to medication. There are no disease-modifying treatments that may be administered briefly to patients to enduringly eliminate spontaneous seizures and reverse cognitive deficits. Applying network approaches to whole tissue and single-nucleus transcriptomic data collected from mouse models of temporal lobe epilepsy and publicly available transcriptomic data from human temporal lobectomy samples, we confirmed a previously described pattern of rapid and transient induction of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway within days of epileptogenic insult. This was followed by a resurgent activation of the JAK/STAT pathway weeks to months later with the onset of spontaneous seizures. Targeting the first wave of JAK/STAT activation after epileptic insult did not prevent seizures. However, inhibition of the second wave with CP690550 (tofacitinib) over a 2-week period enduringly suppressed seizures, rescued deficits in spatial memory, and alleviated epilepsy-associated histopathological alterations. Seizure suppression lasted for at least 2 months after the final dose. These results indicate that reignition of inflammatory JAK/STAT3 signaling in chronic epilepsy opens a window for disease modification with the US Food and Drug Administration–approved, orally available drug CP690550.

28 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JEJose Ezekiel C. Espina
Jose Ezekiel C. Espina
OHOlivia R. Hoffman
Olivia R. Hoffman
JKJennifer L. Koehler
Jennifer L. Koehler
BSBarry A. Schoenike
Barry A. Schoenike
ARAvtar S. Roopra
Avtar S. Roopra
The processes by which epileptic insults precipitate the molecular, cellular, and network alterations in the brain that lead to epilepsy are poorly understood. We previously discovered that after status epilepticus (SE – an epilepsy inducing severe bout of seizures) the H3K27 methylase Enhancer of Zeste Homolog 2 (EZH2) is robustly induced and drives repression of genes. Both systemic pharmacological inhibition of EZH2 and deletion of EZH2 in neurons exacerbates epilepsy progression, suggesting that acute EZH2 induction may exert a net protective effect against disease progression chronically. However, the mechanisms underlying EZH2-mediated control of the putative protective and pathological pathways in disease progression are still unknown. To interrogate the mechanisms of EZH2 function post-SE, we used bulk CUT&RUN- sequencing against H3K27me3 in tandem with bulk RNA-sequencing in hippocampi of naive and 4d. post-SE mice to profile epigenomic and transcriptomic changes. Differential peak analysis showed that H3K27me3 was enriched both at loci pre-marked by H3K27me3 in the naive hippocampus as well as in loci that were de novo methylated after SE, consistent with the SE-dependent induction of EZH2 protein levels. Multi-omic integration of CUT&RUN and RNA-seq data revealed a module of genes that were coordinately H3K27me3 enriched, transcriptionally repressed, and annotated to ontological terms involved in neuronal signaling and network excitability. This result suggests that EZH2 induction may function in part to control network excitability after injury. To test this, we treated mice acutely post-SE with the EZH2 inhibitor UNC1999 and found that EZH2 inhibition attenuated H3K27me3 induction and dampened repression of target network excitability genes in response to SE. Functionally, UNC1999 treatment significantly increased seizure probability acutely and exacerbated disease severity in the chronic period. Taken together, these results suggest that EZH2 induction after injury may function to maintain network excitability to lower seizure probability acutely to protect against disease progression.

12 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JKJennifer Koehler
Jennifer Koehler
OHOlivia R. Hoffman
Olivia R. Hoffman
QHQuinn Rose Harvey
Quinn Rose Harvey
BSBarry A. Schoenike
Barry A. Schoenike
JEJose Ezekiel Clemente Espina
Jose Ezekiel Clemente Espina
ARAvtar S. Roopra
Avtar S. Roopra
One-third of people with epilepsy continue to have seizures despite antiseizure medications (ASMs), and available therapies often fail to improve disabling cognitive comorbidities. Patients with drug resistant epilepsy report that the adverse effects of medications along with their comorbidities can have a greater negative impact on the quality of life than seizures. We previously identified recurrent JAK/STAT3 activation in chronic epilepsy and showed that transient treatment with the JAK inhibitor tofacitinib (CP690550) durably suppresses seizures and restores cognition in mice. Here, we tested CP690550 as an add-on therapy after failure of carbamazepine (CBZ), a common first line treatment for epilepsy, in a mouse model of multifocal temporal lobe epilepsy. In CBZ-resistant animals, dual therapy with CP690550 reduced median seizure frequency and time spent seizing by an order of magnitude; most dual therapy responders had no observed behavioral seizures during treatment. CP690550 also restored spatial working and short-term memory. We found that cognitive rescue was independent of seizure response. Our work suggests that JAK/STAT inhibition can overcome ASM nonresponse while independently improving epilepsy-associated cognitive dysfunction.